Gue, Ying X <br/><br/>
Rationale and design of "Can Very Low Dose Rivaroxaban (VLDR) in addition to dual antiplatelet therapy improve thrombotic status in acute coronary syndrome (VaLiDate-R)" study : A randomised trial modulating endogenous fibrinolysis in patients with acute coronary syndrome.  [electronic resource] 

 -  Journal of thrombosis and thrombolysis  Feb 2020 
 - 192-198 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1573-742X 
<br/><br/><label>Standard No.: </label>10.1007/s11239-019-02014-5  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Acute Coronary Syndrome--blood<br/>Clopidogrel--administration & dosage<br/>Dose-Response Relationship, Drug<br/>Dual Anti-Platelet Therapy--methods<br/>Factor Xa Inhibitors--administration & dosage<br/>Female<br/>Fibrinolysis--drug effects<br/>Humans<br/>Male<br/>Platelet Aggregation Inhibitors--administration & dosage<br/>Rivaroxaban--administration & dosage<br/>Thrombelastography--methods<br/>Thrombosis--blood<br/>Ticagrelor--administration & dosage